Current gout treatment and flare in South Korea: Prophylactic duration associated with fewer gout flares
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, H.J. | - |
dc.contributor.author | Lee, C.H. | - |
dc.contributor.author | Lee, J.H. | - |
dc.contributor.author | Yoon, B.Y. | - |
dc.contributor.author | Kim, H.A. | - |
dc.contributor.author | Suh, C.H. | - |
dc.contributor.author | Choi, S.T. | - |
dc.contributor.author | Song, J.S. | - |
dc.contributor.author | Joo, H.Y. | - |
dc.contributor.author | Choi, S.J. | - |
dc.contributor.author | Lee, J.S. | - |
dc.contributor.author | Shin, K.C. | - |
dc.contributor.author | Baek, H.J. | - |
dc.date.available | 2019-03-08T11:38:31Z | - |
dc.date.issued | 2017-06 | - |
dc.identifier.issn | 1756-1841 | - |
dc.identifier.issn | 1756-185X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/6121 | - |
dc.description.abstract | Aim: To evaluate treatment patterns and clinical factors affecting gout flare in South Korea. Methods: We retrospectively examined data from 401 patients seen at nine rheumatology multicenter clinics, under urate lowering therapy (ULT) more than 6 months after stopping prophylactic medication. Demographic data, clinical and laboratory features were collected at the initiation of ULT, upon stopping prophylaxis, and 6 months after. Results: The mean age was 52.2 years and mean disease duration was 25.0 months. The male-to-female count was 387 : 14. The most common ULT starting agent was allopurinol 83.8%. Colchicine (62.3%) was the most commonly prescribed prophylactic agent. During ULT, 134 of the 401 patients (33.4%) experienced at least one gouty attack in the period from stopping prophylaxis to 6 months later. The duration of prophylaxis was different between those with serum uric acid levels below 6 mg/dL and those over 6 mg/dL (P = 0.001). Of the 179 patients (44.6%) who attained target serum uric acid (SUA) levels (6 mg/dL) at the end of prophylaxis, those taking < 6 months of prophylaxis suffered more frequent flares than those taking it ≥ 6 months (42.9% vs. 26.3%, P = 0.041). The time interval to the first attack after stopping prophylaxis was shorter in the < 6 months group than the ≥ 6 months group (13.5 weeks vs. 22.5 weeks, P = 0.007). Conclusions: Prophylaxis more than 6 months from initiation of ULT, and achieving target SUA (< 6 mg/dL) at the time of stopping prophylaxis is associated with fewer gout flares during ULT. © 2014 Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Blackwell Publishing | - |
dc.title | Current gout treatment and flare in South Korea: Prophylactic duration associated with fewer gout flares | - |
dc.type | Article | - |
dc.identifier.doi | 10.1111/1756-185X.12422 | - |
dc.identifier.bibliographicCitation | International Journal of Rheumatic Diseases, v.20, no.4, pp 497 - 503 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000405267300012 | - |
dc.identifier.scopusid | 2-s2.0-85028281849 | - |
dc.citation.endPage | 503 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 497 | - |
dc.citation.title | International Journal of Rheumatic Diseases | - |
dc.citation.volume | 20 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | flare | - |
dc.subject.keywordAuthor | gout treatment | - |
dc.subject.keywordAuthor | prophylactic duration | - |
dc.subject.keywordAuthor | serum uric acid | - |
dc.relation.journalResearchArea | Rheumatology | - |
dc.relation.journalWebOfScienceCategory | Rheumatology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.